• Beigene Ltd ONC.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.41. The mean expectation of ten analysts for the quarter was for a loss of 72 cents per share. Wall Street expected results to range from $-1.06 to -40 cents per share.

• Revenue rose 48.6% to $1.12 billion from a year ago; analysts expected $1.14 billion.

• Beigene Ltd's reported EPS for the quarter was 1 cent​.

• The company reported quarterly net income of $1.27 million.

• Beigene Ltd shares had fallen by 11.2% this quarter and gained 30.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.3% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Beigene Ltd is $320.00

This summary was machine generated from LSEG data May 7 at 03:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)